Company Overview - Jiangxi Sanxin Medical Technology Co., Ltd. specializes in the research, manufacturing, sales, and service of medical devices, with key products including blood purification devices, drug delivery devices, and cardiothoracic surgical instruments [2] - As of the end of 2024, the company holds 203 authorized patents, 121 pending patents, and has published 26 papers, demonstrating a strong commitment to technological innovation and R&D [2] - The company has been recognized as a "National Intellectual Property Advantage Enterprise" by the National Intellectual Property Administration of China [2] Financial Performance - In the first quarter of 2025, the company reported revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, reflecting a slight increase of 0.20% year-on-year [2] - The gross profit margin for the same period was 34.62% [2] Market Position - As of May 28, the company's stock closed at 8.19 yuan, up 4.20%, with a rolling price-to-earnings (PE) ratio of 18.81, marking a new low in 46 days [1] - The average PE ratio for the medical device industry is 48.81, with a median of 35.46, placing Sanxin Medical at the 44th position in the industry ranking [1][3] - The total market capitalization of the company is 4.278 billion yuan [1] Shareholder Information - As of March 31, 2025, the number of shareholders increased to 18,367, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

证券代码：300453 证券简称：三鑫医疗 江西三鑫医疗科技股份有限公司 投资者关系活动记录表 | 编号：20250411 | | --- | | 投资者关系活动 | □特定对象调研 分析师会议 | | | --- | --- | --- | | | □媒体采访 业绩说明会 | | | 类别 | □新闻发布会 路演活动 | | | | 现场参观  其他 电话会议 | | | 参与单位名称 | 相聚资本、华夏基金、华夏久盈、天弘基金 | | | 时间 | 2025年4月11日 | | | 地点 | 电话会议 | | | 上市公司接待 | 董事、副总裁、董事会秘书 刘明 | | | 人员姓名 | | | | | 一、简要介绍公司主营业务等基本情况 | | | | 公司董事、副总裁、董事会秘书刘明先生简要介绍了公司主要业务 | | | | 及 2024 年度经营情况。 | | | | 公司保持一贯稳健的发展态势，2024 | 年实现营业收入 150,043.84 万 | | | 元，较上年同期增长 | 15.41%；实现归属于上市公司股东的净利润为 | | | 22,740.41 万元，较上年同期增长 | ...